The Prospective @entity65  nster Study: prevalence and prognostic significance of hyperlipidemia in XXXX with systemic @entity101 .

@entity1 @entity64 @entity583 @entity6 @entity731 @entity101 @entity412 @entity951 @entity453 @entity204 @entity65 @entity165
The ongoing Prospective @entity65  nster (PROCAM) trial was initiated to identify risk factors for @entity453 ( @entity453 ). By comparing @entity1 ' long-term cardiac status (clinical signs of @entity731 , @entity583 , @entity64 or @entity204 due to @entity731 ) with results from entrance questionnaires, physical examinations, blood pressure measurements, electrocardiograms at rest and blood analyses, the characteristics and strategies for identifying @entity1 in the general population who are at risk for developing @entity453 were to be determined. From PROCAM trial data, 3 predictive criteria for identifying such @entity1 have been determined: They are a total @entity165 /high density lipoprotein (HDL) @entity165 ratio of 6.5 was determined to be the threshold for @entity453 risk. Combined analysis of lipid parameters identified high-risk @entity1 as those with @entity165 values of greater than or equal to 300 mg/dl, and low-risk @entity1 as those with @entity165 and @entity412 values less than 200 mg/dl. The remaining subjects are classified according to their HDL @entity165 values. If the HDL @entity165 value is less than 35 mg/dl, the subject is considered to be at high risk, if HDL @entity165 is greater than or equal to 35 mg/dl the @entity1 is considered to be at average risk. The upper 20% of risk was computed by means of a multiple logistic function based on statistics for age, total @entity165 and HDL @entity165 levels, systolic blood pressure, @entity951 , @entity6 , cigarette smoking and family history of @entity583 . A further analysis was the risk incurred by @entity101 . @entity101 was observed in 16.5% of @entity1 and 13.9% of @entity1 .(ABSTRACT TRUNCATED AT 250 WORDS)
